195 related articles for article (PubMed ID: 38413797)
1. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.
Chen H; Yu S; Ma R; Deng L; Yi Y; Niu M; Xu C; Xiao ZJ
Cell Death Differ; 2024 Apr; 31(4):447-459. PubMed ID: 38413797
[TBL] [Abstract][Full Text] [Related]
2. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer.
Chang PH; Chen MC; Tsai YP; Tan GYT; Hsu PH; Jeng YM; Tsai YF; Yang MH; Hwang-Verslues WW
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431674
[TBL] [Abstract][Full Text] [Related]
3. EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin.
Tong ZT; Cai MY; Wang XG; Kong LL; Mai SJ; Liu YH; Zhang HB; Liao YJ; Zheng F; Zhu W; Liu TH; Bian XW; Guan XY; Lin MC; Zeng MS; Zeng YX; Kung HF; Xie D
Oncogene; 2012 Feb; 31(5):583-94. PubMed ID: 21685935
[TBL] [Abstract][Full Text] [Related]
4. A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia.
Wang X; Wang Y; Li L; Xue X; Xie H; Shi H; Hu Y
Oncogene; 2020 Feb; 39(9):1860-1874. PubMed ID: 31784651
[TBL] [Abstract][Full Text] [Related]
5. Hypoxic ER stress suppresses β-catenin expression and promotes cooperation between the transcription factors XBP1 and HIF1α for cell survival.
Xia Z; Wu S; Wei X; Liao Y; Yi P; Liu Y; Liu J; Liu J
J Biol Chem; 2019 Sep; 294(37):13811-13821. PubMed ID: 31350332
[TBL] [Abstract][Full Text] [Related]
6. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
7. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
8. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
9. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
10. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
[TBL] [Abstract][Full Text] [Related]
11. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.
Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA
Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072
[TBL] [Abstract][Full Text] [Related]
12. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
[TBL] [Abstract][Full Text] [Related]
13. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway.
Sun CC; Zhu W; Li SJ; Hu W; Zhang J; Zhuo Y; Zhang H; Wang J; Zhang Y; Huang SX; He QQ; Li DJ
Genome Med; 2020 Sep; 12(1):77. PubMed ID: 32878637
[TBL] [Abstract][Full Text] [Related]
14. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
[TBL] [Abstract][Full Text] [Related]
15. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract][Full Text] [Related]
16. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Ramsey MR; He L; Forster N; Ory B; Ellisen LW
Cancer Res; 2011 Jul; 71(13):4373-9. PubMed ID: 21527555
[TBL] [Abstract][Full Text] [Related]
17. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
18. Noncanonical TGF-β signaling leads to FBXO3-mediated degradation of ΔNp63α promoting breast cancer metastasis and poor clinical prognosis.
Niu M; He Y; Xu J; Ding L; He T; Yi Y; Fu M; Guo R; Li F; Chen H; Chen YG; Xiao ZJ
PLoS Biol; 2021 Feb; 19(2):e3001113. PubMed ID: 33626035
[TBL] [Abstract][Full Text] [Related]
19. DeltaNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation.
Qian Y; Jung YS; Chen X
J Biol Chem; 2011 Apr; 286(14):12033-41. PubMed ID: 21317427
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer.
Mabe NW; Fox DB; Lupo R; Decker AE; Phelps SN; Thompson JW; Alvarez JV
J Clin Invest; 2018 Oct; 128(10):4413-4428. PubMed ID: 30148456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]